Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06431607 · ClinicalTrials.gov registry record · Phase 2
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 845
- Enrollment target
NCT06431607 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 845 participants.
The verdict
NCT06431607, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 845 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
Interventions
- BIOLOGICAL F2G22B/DL001Z
- BIOLOGICAL F2H23D/DL001Z-NH
- BIOLOGICAL F2H23B/DL001Z-NH
- BIOLOGICAL F2H23H/DL001Z
- COMBINATION_PRODUCT FDQ23A-NH (Flu D-QIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 845 participants |
| Start Date | 2024-05-23 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06431607
The ClinicalTrials.gov registry entry for NCT06431607 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 845 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which F2G22B/DL001Z is the first listed.
NCT06431607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06431607 about?
NCT06431607 is a clinical study titled "A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults". The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
What is the current status of trial NCT06431607?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 845 participants. The study started on 2024-05-23. Estimated completion is 2025-06-04.
What interventions are being tested in trial NCT06431607?
The interventions under investigation include: F2G22B/DL001Z (BIOLOGICAL), F2H23D/DL001Z-NH (BIOLOGICAL), F2H23B/DL001Z-NH (BIOLOGICAL), F2H23H/DL001Z (BIOLOGICAL), FDQ23A-NH (Flu D-QIV) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06431607?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.